Summary

Eligibility
for people ages 12 months to 21 years (full criteria)
Location
at UCSF
Dates
study started
study ends around
Principal Investigator
by Jennifer Michlitsch, MD (ucsf)
Headshot of Jennifer Michlitsch
Jennifer Michlitsch

Description

Summary

This is a prospective, multicenter clinical trial in subjects with newly diagnosed high-risk neuroblastoma to evaluate the efficacy and safety of administering naxitamab with standard induction therapy. The initial chemotherapy will include 5 cycles of multi-agent chemotherapy. Naxitamab will be added to all 5 Induction cycles. We hypothesize that the addition of anti-GD2 therapy to induction chemotherapy will result in improved end of induction responses and improved survival.

Official Title

A Phase II Study of Naxitamab Added to Induction Therapy for Subjects With Newly Diagnosed High-Risk Neuroblastoma

Details

Keywords

High-risk Neuroblastoma, naxitimab, induction, Neuroblastoma, Ceritinib, Naxitamab

Eligibility

Locations

  • UCSF Benioff Children's Hospital Oakland- accepting new patients
    Oakland California 94609 United States
  • Dell Children's Blood and Cancer Center accepting new patients
    Austin Texas 78723 United States

Lead Scientist at University of California Health

  • Jennifer Michlitsch, MD (ucsf)
    Professor, Pediatrics, School of Medicine. Authored (or co-authored) 23 research publications

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Giselle Sholler
Links
Beat Childhood Cancer Consortium website
ID
NCT05489887
Phase
Phase 2 Neuroblastoma Research Study
Study Type
Interventional
Participants
Expecting 76 study participants
Last Updated